Cochrane · systematic review · CD010482
Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer
Lawrie, TA, Rabbie, R, Thoma, C, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 6 · 100%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: women with newly diagnosed EOC (stage Ic to IV)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PFS¹ | HR 1.01 [0.85, 1.19] | 1 study · 820 participants | High |
OS² | HR 0.94 [0.78, 1.13] | 1 study · 820 participants | High |
Anaemia (grade 3/4) | RR 2.74 [1.54, 4.88] | 1 study · 803 participants | High |
Thrombocytopenia (grade 3/4) | RR 8.09 [3.93, 16.67] | 1 study · 803 participants | High |
Alopecia (grade 2) | RR 0.09 [0.06, 0.14] | 1 study · 803 participants | High |
Neuropathy (grade 3/4) | RR 0.09 [0.01, 0.66] | 1 study · 803 participants | High |